Literature DB >> 411404

Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium Tuberculosis.

J M Dickinson, V R Aber, D A Mitchison.   

Abstract

Log-phase cultures of Mycobacterium tuberculosis in Tween-albumin medium were exposed to streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide in concentrations in the range likely to be present in serum during treatment of patients. The bactericidal activity of the drugs was measured as the decrease in viable counts at 4 and 7 days. The activity of single drugs was highest for streptomycin and next highest for rifampin and isoniazid, but ethambutol only started to kill after 4 days. When exposed to 2 drugs, bactericidal synergism was found with streptomycin/isoniazid and isoniazid/ethambutol; additivity, with streptomycin/rifampin; indifference, with isoniazid rifampin and streptomycin/ethambutol; and antagonism, with rifampin/ethambutol and isoniazid/pyrazinamide. When cultures were exposed to the 3 drugs, isoniazid, rifampin, and ethambutol, marked antagonism was found between isoniazid and rifampin, whereas the addition of isoniazid or an increase in its concentration increased the bactericidal activity.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 411404     DOI: 10.1164/arrd.1977.116.4.627

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  20 in total

1.  Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis.

Authors:  L Heifets; P Lindholm-Levy
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

2.  Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.

Authors:  Mary A De Groote; Janet C Gilliland; Colby L Wells; Elizabeth J Brooks; Lisa K Woolhiser; Veronica Gruppo; Charles A Peloquin; Ian M Orme; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

3.  The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model.

Authors:  G L Drusano; Nicole Sgambati; Adam Eichas; David L Brown; Robert Kulawy; Arnold Louie
Journal:  MBio       Date:  2010-08-10       Impact factor: 7.867

4.  Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide.

Authors:  J Dhillon; J M Dickinson; K Sole; D A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

5.  In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis.

Authors:  T Yamamoto; R Amitani; K Suzuki; E Tanaka; T Murayama; F Kuze
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

6.  Noninvasive determination of 2-[18F]-fluoroisonicotinic acid hydrazide pharmacokinetics by positron emission tomography in Mycobacterium tuberculosis-infected mice.

Authors:  E A Weinstein; L Liu; A A Ordonez; H Wang; J M Hooker; P J Tonge; S K Jain
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

7.  Assessing the Combined Antibacterial Effect of Isoniazid and Rifampin on Four Mycobacterium tuberculosis Strains Using In Vitro Experiments and Response-Surface Modeling.

Authors:  Oana Dumitrescu; Sylvain Goutelle; Charlotte Genestet; Florence Ader; Catherine Pichat; Gérard Lina
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

8.  Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method.

Authors:  M Salfinger; L B Heifets
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

9.  Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model.

Authors:  Aleidy Silva; Bai-Yu Lee; Daniel L Clemens; Theodore Kee; Xianting Ding; Chih-Ming Ho; Marcus A Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-28       Impact factor: 11.205

10.  Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.

Authors:  N B Bhatt; C Barau; A Amin; E Baudin; B Meggi; C Silva; V Furlan; B Grinsztejn; A Barrail-Tran; M Bonnet; A M Taburet
Journal:  Antimicrob Agents Chemother       Date:  2014-03-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.